We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318991

CAS#: 7481-89-2

Description: Zalcitabine, also called dideoxycytidine, is a nucleoside analog reverse transcriptase inhibitor (NARTI) sold under the trade name Hivid. Zalcitabine was the third antiretroviral to be approved by the Food and Drug Administration (FDA) for the treatment of HIV/AIDS. It is used as part of a combination regimen. Zalcitabine appears less potent than some other nucleoside RTIs, has an inconvenient three-times daily frequency and is associated with serious adverse events. For these reasons it is now rarely used to treat human immunodeficiency virus (HIV), and it has even been removed from pharmacies entirely in some countries.

Price and Availability

Size Price Shipping out time Quantity
100mg USD 250 2 Weeks
250mg USD 465 2 Weeks
500mg USD 725 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2020-10-30. Prices are subject to change without notice.

Zalcitabine, purity > 95%, is in stock. Current shipping out time is about 2 weeks after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide). Shipping fee: from $30.00 (USA); from $45.00 (Canada); from $70.00 (international).

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 318991
Name: Zalcitabine
CAS#: 7481-89-2
Chemical Formula: C9H13N3O3
Exact Mass: 211.09569
Molecular Weight: 211.221
Elemental Analysis: C, 51.18; H, 6.20; N, 19.89; O, 22.72

Synonym: NSC606170; NSC 606170; NSC-606170; Zalcitabine; 2′-3′-dideoxycytidine; ddC; dideoxycytidine, Brand name: Hivid.

IUPAC/Chemical Name: 4-amino-1-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one


InChi Code: InChI=1S/C9H13N3O3/c10-7-3-4-12(9(14)11-7)8-2-1-6(5-13)15-8/h3-4,6,8,13H,1-2,5H2,(H2,10,11,14)/t6-,8+/m0/s1

SMILES Code: O=C1N=C(N)C=CN1[C@@H]2O[C@H](CO)CC2

Technical Data

Solid powder

>95% (or refer to the Certificate of Analysis)

Safety Data Sheet (SDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Carey P. Peripheral neuropathy: zalcitabine reassessed. Int J STD AIDS. 2000 Jul;11(7):417-23. Review. PubMed PMID: 10919481.

2: Darbyshire J, Foulkes M, Peto R, Duncan W, Babiker A, Collins R, Hughes M, Peto T, Walker A. Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults. Cochrane Database Syst Rev. 2000;(3):CD002038. Review. PubMed PMID: 10908523.

3: Darbyshire J, Foulkes M, Peto R, Duncan W, Babiker A, Collins R, Hughes M, Peto T, Walker A. Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults. Cochrane Database Syst Rev. 2000;(2):CD002038. Review. Update in: Cochrane Database Syst Rev. 2000;(3):CD002038. PubMed PMID: 10796851.

4: Moyle GJ, Gazzard BG. Finding a role for zalcitabine in the HAART era. Antivir Ther. 1998;3(3):125-37. Review. PubMed PMID: 10682130.

5: Adkins JC, Peters DH, Faulds D. Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection. Drugs. 1997 Jun;53(6):1054-80. Review. PubMed PMID: 9179531.

6: Craig C, Moyle G. The development of resistance of HIV-1 to zalcitabine. AIDS. 1997 Mar;11(3):271-9. Review. PubMed PMID: 9147417.

7: Skowron G. ddC (zalcitabine). Adv Exp Med Biol. 1996;394:257-69. Review. PubMed PMID: 8815690.

8: Devineni D, Gallo JM. Zalcitabine. Clinical pharmacokinetics and efficacy. Clin Pharmacokinet. 1995 May;28(5):351-60. Review. PubMed PMID: 7614775.

9: Jablonowski H. Studies of zidovudine in combination with didanosine and zalcitabine. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 1:S52-6. Review. PubMed PMID: 8595509.

10: Shelton MJ, O'Donnell AM, Morse GD. Zalcitabine. Ann Pharmacother. 1993 Apr;27(4):480-9. Review. PubMed PMID: 8097417.

11: Lipsky JJ. Zalcitabine and didanosine. Lancet. 1993 Jan 2;341(8836):30-2. Review. PubMed PMID: 8093278.

12: Whittington R, Brogden RN. Zalcitabine. A review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS). Drugs. 1992 Oct;44(4):656-83. Review. PubMed PMID: 1281077.